Pharmaceuticals

Conjugate Vaccine Market Analysis 2025–2029: Growth Forecast and Competitive Insights

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the conjugate vaccine market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Conjugate Vaccine Market Be Worth By 2029, And What CAGR Will It Achieve?

The conjugate vaccine market has expanded considerably in recent years. Its valuation is anticipated to rise from $18.9 billion in 2024 to $21.26 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.5%. The expansion observed historically can be credited to the impact of disease burden, the implementation of government immunization programs, greater public awareness, a strong emphasis on pediatric vaccination, and prevailing preventive healthcare trends.

The conjugate vaccine market is anticipated to show significant expansion in the coming years. This market is projected to achieve a value of “$33.99 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.4%. The projected growth during this period is attributable to factors such as broadening immunization policies, evolving aging population demographics, the emergence of new vaccine indications, heightened global health security concerns, increased international collaboration, and the influence of economic development. Prominent trends expected within the forecast timeframe include improved collaborations and partnerships for vaccine distribution, customized strategies for high-risk populations, the utilization of vaccines against emerging infectious diseases, ongoing advancements in vaccine manufacturing technologies, and various global health initiatives focused on ensuring vaccine equity.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

Which Factors Are Driving The Conjugate Vaccine Market Forward?

The expanded utilization of conjugate vaccines in adults is anticipated to fuel the growth of the conjugate vaccine market. These vaccines are specifically engineered to elicit a robust immune response against bacterial capsular polysaccharides, thereby enhancing the body’s defense mechanisms against bacterial infections. Administering conjugate vaccines to adults helps mitigate the risk of severe illness, complications, and the transmission of these bacterial diseases by stimulating a powerful immune response. For instance, in June 2024, reports from the UK Health Security Agency (UKHSA), a UK-based public health body, indicated that the 12-month coverage for the ‘6-in-1’ vaccine in the UK maintained a stable rate of 91.7%. Furthermore, the initial dose of the pneumococcal conjugate vaccine (PCV) remained at 93.7%. Rotavirus coverage saw an increase of 0.6%, reaching 89.3%, while the second dose of the meningitis B vaccine (MenB2) climbed by 0.1% to 91.5%. Therefore, the rising adoption of conjugate vaccines for adults is a key driver for the conjugate vaccine market’s expansion.

Which Segments Form The Key Structure Of The Conjugate Vaccine Market?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

What Strategic Shifts And Innovations Are Influencing The Conjugate Vaccine Market?

Innovation in conjugate vaccines represents a significant and expanding trend within the conjugate vaccine market. Companies operating in this sector are dedicating their efforts to developing cutting-edge conjugate vaccines to uphold their competitive position in the market. As an example, in June 2022, Pfizer Inc., a pharmaceutical and biotechnology company based in the US, introduced Prevnar 20, a pneumococcal 20-valent conjugate vaccine, in Canada. This vaccine aims to prevent pneumonia and invasive pneumococcal infections in adults aged 18 and older. Prevnar 20 features conjugates for the 13 serotypes that are already included in PREVNAR 13, alongside conjugates for seven supplementary serotypes linked to invasive pneumococcal disease, high case-fatality rates, antibiotic resistance, and meningitis.

Which Firms Are Making The Biggest Impact In The Conjugate Vaccine Market?

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

Which Region Is Expected To Lead The Conjugate Vaccine Market In The Next Few Years?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

Browse Through More Reports Similar to the Global Conjugate Vaccine Market 2025, By The Business Research Company

Cancer Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report

Dtp Vaccine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dtp-vaccine-global-market-report

Companion Animal Veterinary Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/companion-animal-veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795